Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · IEX Real-Time Price · USD
8.40
+0.26 (3.19%)
At close: May 31, 2024, 4:00 PM
8.73
+0.33 (3.93%)
After-hours: May 31, 2024, 6:59 PM EDT
Voyager Therapeutics Market Cap
Voyager Therapeutics has a market cap or net worth of $456.91 million as of May 31, 2024. Its market cap has decreased by -19.83% in one year.
Market Cap
456.91M
Enterprise Value
57.34M
1-Year Change
-19.83%
Ranking
Category
Stock Price
$8.40
Market Cap Chart
Since November 11, 2015, Voyager Therapeutics's market cap has increased from $456.60M to $456.91M, an increase of 0.07%. That is a compound annual growth rate of 0.01%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 31, 2024 | 456.90M | 3.18% |
May 30, 2024 | 442.80M | 4.09% |
May 29, 2024 | 425.40M | -2.36% |
May 28, 2024 | 435.70M | -2.68% |
May 24, 2024 | 447.70M | 1.61% |
May 23, 2024 | 440.60M | -2.41% |
May 22, 2024 | 451.50M | -1.66% |
May 21, 2024 | 459.10M | -0.11% |
May 20, 2024 | 459.60M | 0.24% |
May 17, 2024 | 458.50M | -2.32% |
May 16, 2024 | 469.40M | 0.69% |
May 15, 2024 | 466.20M | 1.06% |
May 14, 2024 | 461.30M | - |
May 13, 2024 | 461.30M | 0.65% |
May 10, 2024 | 458.30M | - |
May 9, 2024 | 458.30M | -1.53% |
May 8, 2024 | 465.40M | -2.27% |
May 7, 2024 | 476.20M | -1.90% |
May 6, 2024 | 485.40M | 1.46% |
May 3, 2024 | 478.40M | 3.28% |
May 2, 2024 | 463.20M | 2.03% |
May 1, 2024 | 454.00M | 6.92% |
Apr 30, 2024 | 424.60M | 0.64% |
Apr 29, 2024 | 421.90M | 1.96% |
Apr 26, 2024 | 413.80M | 2.71% |
View and export this data all the way back to 2015.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Enhabit | 460.43M |
Talkspace | 455.60M |
Larimar Therapeutics | 455.10M |
ZimVie | 453.67M |
TScan Therapeutics | 448.81M |
Terns Pharmaceuticals | 440.45M |
Neurogene | 438.60M |
Oculis Holding AG | 436.84M |